peoplePerson
Keith T. Flaherty
Led the first trials of BRAF inhibition in melanoma and chairs the NCI-MATCH precision medicine trial.
First author of the 2010 vemurafenib (PLX4032) study and leader of the dabrafenib-trametinib combination work; co-chair of NCI-MATCH.
Role
Director of Clinical Research, Mass General Cancer Center
Institution
Specialisms
MelanomaBRAF and MEK inhibitorsPrecision oncology trials
Profiles
| Title | Journal | Year |
|---|---|---|
| Inhibition of mutated, activated BRAF in metastatic melanoma | New England Journal of Medicine | 2010 |
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations | New England Journal of Medicine | 2012 |